ICLE 2022 | CAR T-cell therapy for neuroblastoma

Shigeki Yagyu, MD, PhD, Kyoto Prefectural University of Medicine, Kyoto, Japan, gives an overview of promising chimeric antigen receptor (CAR) T-cell therapies for neuroblastoma. Despite current immunotherapies such as dinutuximab and naxitamab being available, prognoses remain poor in patients. PiggyBac transposon-mediated chimeric antigen receptor (CAR) T-cell therapies represent an alternative option for patients and clinical trials are underway to assess safety and efficacy. The PiggyBac transposon will hopefully solve issues relating to cell exhaustion and tumor control and the technology may potentially be utilized in natural killer (NK) cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.